After PCI and 3 mo of DAPT, P2Y12-inhibitor monotherapy was noninferior to DAPT at 12 mo

Alexander Gallus

doi:10.7326/ACPJ201911190-053

After PCI and 3 mo of DAPT, P2Y12-inhibitor monotherapy was noninferior to DAPT at 12 mo

Alexander Gallus

Flinders University

Research output: Contribution to journal › Comment/debate

1 Citation (Scopus)

Abstract

Question
After percutaneous coronary intervention (PCI) and 3 months of dual-antiplatelet therapy (DAPT), is P2Y12-inhibitor monotherapy noninferior to continued DAPT?

Original language	English
Pages (from-to)	JC53
Number of pages	1
Journal	Annals of Internal Medicine
Volume	171
Issue number	10
DOIs	https://doi.org/10.7326/ACPJ201911190-053
Publication status	Published - 19 Nov 2019

Keywords

randomised controlled trial
thrombosis
percutaneous coronary intervention
Angioplasty
Antagonist Monotherapy
Dual Antiplatelet Therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.7326/ACPJ201911190-053Licence: In Copyright

Cite this

@article{d08e5cc782c041cf89d5dc2dc31c3d42,

title = "After PCI and 3 mo of DAPT, P2Y12-inhibitor monotherapy was noninferior to DAPT at 12 mo",

abstract = "QuestionAfter percutaneous coronary intervention (PCI) and 3 months of dual-antiplatelet therapy (DAPT), is P2Y12-inhibitor monotherapy noninferior to continued DAPT?",

keywords = "randomised controlled trial, thrombosis, percutaneous coronary intervention, Angioplasty, Antagonist Monotherapy, Dual Antiplatelet Therapy",

author = "Alexander Gallus",

year = "2019",

month = nov,

day = "19",

doi = "10.7326/ACPJ201911190-053",

language = "English",

volume = "171",

pages = "JC53",

journal = "Annals of Internal Medicine",

issn = "0003-4819",

publisher = "American College of Physicians",

number = "10",

}

TY - JOUR

T1 - After PCI and 3 mo of DAPT, P2Y12-inhibitor monotherapy was noninferior to DAPT at 12 mo

AU - Gallus, Alexander

PY - 2019/11/19

Y1 - 2019/11/19

N2 - QuestionAfter percutaneous coronary intervention (PCI) and 3 months of dual-antiplatelet therapy (DAPT), is P2Y12-inhibitor monotherapy noninferior to continued DAPT?

AB - QuestionAfter percutaneous coronary intervention (PCI) and 3 months of dual-antiplatelet therapy (DAPT), is P2Y12-inhibitor monotherapy noninferior to continued DAPT?

KW - randomised controlled trial

KW - thrombosis

KW - percutaneous coronary intervention

KW - Angioplasty

KW - Antagonist Monotherapy

KW - Dual Antiplatelet Therapy

UR - http://www.scopus.com/inward/record.url?scp=85075115131&partnerID=8YFLogxK

U2 - 10.7326/ACPJ201911190-053

DO - 10.7326/ACPJ201911190-053

M3 - Comment/debate

C2 - 31739336

AN - SCOPUS:85075115131

SN - 0003-4819

VL - 171

SP - JC53

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

IS - 10

ER -

After PCI and 3 mo of DAPT, P2Y12-inhibitor monotherapy was noninferior to DAPT at 12 mo

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this